TIMP2 and cancer: Overexpression of miR-17-5p has been reported in multiple cancers, including lung [24], breast [25], colorectal [26], prostate [27], and CC [28,29], where it enhances cell proliferation, migration, and invasion by targeting transforming growth-factor-β receptor 2 (TGFBR2) and TIMP2, facilitating extracellular matrix degradation and epithelial–mesenchymal transition [28,30].